<exch:exchange-document country="WO" doc-number="2022259205" kind="A1" doc-id="584641170" date-publ="20221215" family-id="82558028" is-representative="YES" date-of-last-exchange="20230219" date-added-docdb="20221216" originating-office="EP"><exch:bibliographic-data><exch:publication-reference data-format="docdb"><document-id lang="en"><country>WO</country><doc-number>2022259205</doc-number><kind>A1</kind><date>20221215</date></document-id></exch:publication-reference><exch:publication-reference data-format="epodoc"><document-id lang="en"><doc-number>WO2022259205</doc-number></document-id></exch:publication-reference><exch:publication-reference data-format="original"><document-id><doc-number>2022/259205</doc-number></document-id></exch:publication-reference><exch:extended-kind-code>x</exch:extended-kind-code><exch:classifications-ipcr><classification-ipcr sequence="1"><text>A61K   8/04        20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>A61K   9/00        20060101AFI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="3"><text>A61K   9/107       20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="4"><text>A61K  31/366       20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="5"><text>A61K  31/4166      20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="6"><text>A61K  31/57        20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="7"><text>A61K  31/575       20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="8"><text>A61K  31/675       20060101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="9"><text>A61K  47/10        20170101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="10"><text>A61K  47/14        20170101ALI20221215BHEP        </text></classification-ipcr><classification-ipcr sequence="11"><text>A61K  47/42        20170101ALI20221215BHEP        </text></classification-ipcr></exch:classifications-ipcr><exch:patent-classifications><patent-classification sequence="1"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K   9/1075      </classification-symbol><symbol-position>F</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220809</date></action-date></patent-classification><patent-classification sequence="2"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K   8/064       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221020</date></action-date></patent-classification><patent-classification sequence="3"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K   8/375       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221020</date></action-date></patent-classification><patent-classification sequence="4"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K   8/922       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221020</date></action-date></patent-classification><patent-classification sequence="5"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K   9/0043      </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220809</date></action-date></patent-classification><patent-classification sequence="6"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  31/366       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220928</date></action-date></patent-classification><patent-classification sequence="7"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  31/4166      </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220928</date></action-date></patent-classification><patent-classification sequence="8"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  31/57        </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220928</date></action-date></patent-classification><patent-classification sequence="9"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  31/575       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220928</date></action-date></patent-classification><patent-classification sequence="10"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  31/675       </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220928</date></action-date></patent-classification><patent-classification sequence="11"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  47/10        </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220809</date></action-date></patent-classification><patent-classification sequence="12"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  47/14        </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220809</date></action-date></patent-classification><patent-classification sequence="13"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K  47/42        </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20220809</date></action-date></patent-classification><patent-classification sequence="14"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K2800/10        </classification-symbol><symbol-position>L</symbol-position><classification-value>A</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221020</date></action-date></patent-classification><patent-classification sequence="15"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61K2800/21        </classification-symbol><symbol-position>L</symbol-position><classification-value>A</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221020</date></action-date></patent-classification><patent-classification sequence="16"><classification-scheme office="EP" scheme="CPCI"><date>20130101</date></classification-scheme><classification-symbol>A61Q  19/00        </classification-symbol><symbol-position>L</symbol-position><classification-value>I</classification-value><classification-status>B</classification-status><classification-data-source>H</classification-data-source><generating-office>EP</generating-office><action-date><date>20221020</date></action-date></patent-classification></exch:patent-classifications><exch:application-reference is-representative="YES" doc-id="574950146" data-format="docdb"><document-id><country>IB</country><doc-number>2022055385</doc-number><kind>W</kind><date>20220609</date></document-id></exch:application-reference><exch:application-reference data-format="epodoc"><document-id><doc-number>WO2022IB55385</doc-number></document-id></exch:application-reference><exch:application-reference data-format="original"><document-id><doc-number>IB2022/055385</doc-number></document-id></exch:application-reference><exch:language-of-filing>en</exch:language-of-filing><exch:priority-claims><exch:priority-claim sequence="1" data-format="docdb"><document-id><country>PT</country><doc-number>11728321</doc-number><kind>A</kind><date>20210611</date></document-id><exch:priority-active-indicator>Y</exch:priority-active-indicator></exch:priority-claim><exch:priority-claim sequence="1" data-format="epodoc"><document-id><doc-number>PT20210117283</doc-number></document-id></exch:priority-claim><exch:priority-claim sequence="1" data-format="original"><document-id><doc-number>117283</doc-number></document-id></exch:priority-claim></exch:priority-claims><exch:parties><exch:applicants><exch:applicant sequence="1" data-format="docdb"><exch:applicant-name><name>UNIV DA BEIRA INTERIOR</name></exch:applicant-name><residence><country>PT</country></residence></exch:applicant><exch:applicant sequence="1" data-format="docdba"><exch:applicant-name><name>UNIVERSIDADE DA BEIRA INTERIOR</name></exch:applicant-name></exch:applicant></exch:applicants><exch:inventors><exch:inventor sequence="1" data-format="docdb"><exch:inventor-name><name>OLIVEIRA DOS SANTOS ADRIANA</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="2" data-format="docdb"><exch:inventor-name><name>CARVALHO FERNANDES MARIANA</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="3" data-format="docdb"><exch:inventor-name><name>CABRAL PIRES PATRÍCIA SOFIA</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="4" data-format="docdb"><exch:inventor-name><name>LOURENÇO ALVES GILBERTO</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="5" data-format="docdb"><exch:inventor-name><name>MARICOTO FAZENDEIRO ANA CAROLINA</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="6" data-format="docdb"><exch:inventor-name><name>MATOS SILVA PEREIRA NINA FRANCISCA</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="7" data-format="docdb"><exch:inventor-name><name>DA SILVA FERREIRA GOMES MARIA DE FÁTIMA</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="8" data-format="docdb"><exch:inventor-name><name>ESTEVES RODRIGUES LINA ISABEL</name></exch:inventor-name><residence><country>PT</country></residence></exch:inventor><exch:inventor sequence="1" data-format="docdba"><exch:inventor-name><name>OLIVEIRA DOS SANTOS, Adriana</name></exch:inventor-name></exch:inventor><exch:inventor sequence="2" data-format="docdba"><exch:inventor-name><name>CARVALHO FERNANDES, Mariana</name></exch:inventor-name></exch:inventor><exch:inventor sequence="3" data-format="docdba"><exch:inventor-name><name>CABRAL PIRES, Patrícia Sofia</name></exch:inventor-name></exch:inventor><exch:inventor sequence="4" data-format="docdba"><exch:inventor-name><name>LOURENÇO ALVES, Gilberto</name></exch:inventor-name></exch:inventor><exch:inventor sequence="5" data-format="docdba"><exch:inventor-name><name>MARICOTO FAZENDEIRO, Ana Carolina</name></exch:inventor-name></exch:inventor><exch:inventor sequence="6" data-format="docdba"><exch:inventor-name><name>MATOS SILVA PEREIRA NINA, Francisca</name></exch:inventor-name></exch:inventor><exch:inventor sequence="7" data-format="docdba"><exch:inventor-name><name>DA SILVA FERREIRA GOMES, Maria De Fátima</name></exch:inventor-name></exch:inventor><exch:inventor sequence="8" data-format="docdba"><exch:inventor-name><name>ESTEVES RODRIGUES, Lina Isabel</name></exch:inventor-name></exch:inventor></exch:inventors></exch:parties><exch:designation-of-states><exch:designation-pct><exch:regional><region><country>AP</country></region><country>BW</country><country>GH</country><country>GM</country><country>KE</country><country>LR</country><country>LS</country><country>MW</country><country>MZ</country><country>NA</country><country>RW</country><country>SD</country><country>SL</country><country>SZ</country><country>TZ</country><country>UG</country><country>ZM</country><country>ZW</country></exch:regional><exch:regional><region><country>EA</country></region><country>AM</country><country>AZ</country><country>BY</country><country>KG</country><country>KZ</country><country>RU</country><country>TJ</country><country>TM</country></exch:regional><exch:regional><region><country>EP</country></region><country>AL</country><country>AT</country><country>BE</country><country>BG</country><country>CH</country><country>CY</country><country>CZ</country><country>DE</country><country>DK</country><country>EE</country><country>ES</country><country>FI</country><country>FR</country><country>GB</country><country>GR</country><country>HR</country><country>HU</country><country>IE</country><country>IS</country><country>IT</country><country>LT</country><country>LU</country><country>LV</country><country>MC</country><country>MK</country><country>MT</country><country>NL</country><country>NO</country><country>PL</country><country>PT</country><country>RO</country><country>RS</country><country>SE</country><country>SI</country><country>SK</country><country>SM</country><country>TR</country></exch:regional><exch:regional><region><country>OA</country></region><country>BF</country><country>BJ</country><country>CF</country><country>CG</country><country>CI</country><country>CM</country><country>GA</country><country>GN</country><country>GQ</country><country>GW</country><country>KM</country><country>ML</country><country>MR</country><country>NE</country><country>SN</country><country>TD</country><country>TG</country><country>ST</country></exch:regional><exch:national><country>AE</country><country>AG</country><country>AL</country><country>AM</country><country>AO</country><country>AT</country><country>AU</country><country>AZ</country><country>BA</country><country>BB</country><country>BG</country><country>BH</country><country>BN</country><country>BR</country><country>BW</country><country>BY</country><country>BZ</country><country>CA</country><country>CH</country><country>CL</country><country>CN</country><country>CO</country><country>CR</country><country>CU</country><country>CZ</country><country>DE</country><country>DJ</country><country>DK</country><country>DM</country><country>DO</country><country>DZ</country><country>EC</country><country>EE</country><country>EG</country><country>ES</country><country>FI</country><country>GB</country><country>GD</country><country>GE</country><country>GH</country><country>GM</country><country>GT</country><country>HN</country><country>HR</country><country>HU</country><country>ID</country><country>IL</country><country>IN</country><country>IQ</country><country>IR</country><country>IS</country><country>IT</country><country>JM</country><country>JO</country><country>JP</country><country>KE</country><country>KG</country><country>KH</country><country>KN</country><country>KP</country><country>KR</country><country>KW</country><country>KZ</country><country>LA</country><country>LC</country><country>LK</country><country>LR</country><country>LS</country><country>LU</country><country>LY</country><country>MA</country><country>MD</country><country>ME</country><country>MG</country><country>MK</country><country>MN</country><country>MW</country><country>MX</country><country>MY</country><country>MZ</country><country>NA</country><country>NG</country><country>NI</country><country>NO</country><country>NZ</country><country>OM</country><country>PA</country><country>PE</country><country>PG</country><country>PH</country><country>PL</country><country>PT</country><country>QA</country><country>RO</country><country>RS</country><country>RU</country><country>RW</country><country>SA</country><country>SC</country><country>SD</country><country>SE</country><country>SG</country><country>SK</country><country>SL</country><country>ST</country><country>SV</country><country>SY</country><country>TH</country><country>TJ</country><country>TM</country><country>TN</country><country>TR</country><country>TT</country><country>TZ</country><country>UA</country><country>UG</country><country>US</country><country>UZ</country><country>VC</country><country>VN</country><country>WS</country><country>ZA</country><country>ZM</country><country>ZW</country></exch:national></exch:designation-pct></exch:designation-of-states><exch:invention-title lang="en" data-format="docdba">SELF-EMULSIFYING COMPOSITION, PRODUCTION METHODS AND USES THEREOF</exch:invention-title><exch:invention-title lang="fr" data-format="docdba">COMPOSITION AUTO-ÉMULSIFIANTE, SES PROCÉDÉS DE PRODUCTION ET SES UTILISATIONS</exch:invention-title><exch:dates-of-public-availability><exch:examined-printed-without-grant><document-id><date>20221215</date></document-id></exch:examined-printed-without-grant></exch:dates-of-public-availability><exch:references-cited><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="1"><nplcit num="1" npl-type="s" extracted-xp="055966431"><text>BEZERRA-SOUZA ADRIANA ET AL: "Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis", PHARMACEUTICS, vol. 11, no. 7, 1 July 2019 (2019-07-01), CH, pages 353, XP055966431, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics11070353</text><article><author><name>BEZERRA-SOUZA ADRIANA ET AL</name></author><atl>Repurposing Butenafine as An Oral Nanomedicine for Visceral Leishmaniasis</atl><serial><sertitle>PHARMACEUTICS</sertitle><imprint><address><text>CH</text></address><name></name></imprint><pubdate><sdate>20190701</sdate></pubdate><vid>11</vid><ino>7</ino><doi>10.3390/pharmaceutics11070353</doi><issn>1999-4923</issn></serial><location><pp><ppf>353</ppf></pp></location></article></nplcit><rel-passage><passage><pp>A</pp></passage><passage><pp>7</pp><table>2</table>Experiments: 4,7,12,16</passage><passage><pp>7</pp><para>3.2</para><ppl>8</ppl><paral>first</paral>Combination A</passage><passage><pp>3</pp><para>2.1, 2.4</para></passage><category>X</category><rel-claims>1-3,10,13-16,26-32</rel-claims><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>XY</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="2"><nplcit num="2" npl-type="s" extracted-xp="036328597"><text>ELKADI SHAIMAA ET AL: "The Development of Self-nanoemulsifying Liquisolid Tablets to Improve the Dissolution of Simvastatin", AAPS PHARMSCITECH, SPRINGER US, NEW YORK, vol. 18, no. 7, 24 February 2017 (2017-02-24), pages 2586 - 2597, XP036328597, DOI: 10.1208/S12249-017-0743-Z</text><article><author><name>ELKADI SHAIMAA ET AL</name></author><atl>The Development of Self-nanoemulsifying Liquisolid Tablets to Improve the Dissolution of Simvastatin</atl><serial><sertitle>AAPS PHARMSCITECH, SPRINGER US, NEW YORK</sertitle><pubdate><sdate>20170224</sdate></pubdate><vid>18</vid><ino>7</ino><doi>10.1208/S12249-017-0743-Z</doi></serial><location><pp><ppf>2586</ppf><ppl>2597</ppl></pp></location></article></nplcit><rel-passage><passage><table>1</table></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="3"><nplcit num="3" npl-type="w" extracted-xp="055966780"><text>KADU PAWAN J. ET AL: "Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS)", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 16, no. 1, 24 February 2011 (2011-02-24), US, pages 65 - 74, XP055966780, ISSN: 1083-7450, Retrieved from the Internet &lt;URL:http://dx.doi.org/10.3109/10837450903499333&gt; DOI: 10.3109/10837450903499333</text><online><author><name>KADU PAWAN J. ET AL</name></author><online-title>Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS)</online-title><serial><sertitle>PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY</sertitle><imprint><address><text>US</text></address><name></name></imprint><vid>16</vid><ino>1</ino><doi>10.3109/10837450903499333</doi><issn>1083-7450</issn></serial><pubdate><sdate>20110224</sdate></pubdate><location><pp><ppf>65</ppf><ppl>74</ppl></pp></location><avail>http://dx.doi.org/10.3109/10837450903499333</avail></online></nplcit><rel-passage><passage><pp>A</pp></passage><passage><table>1</table>Formulations F1-F6</passage><passage><table>2-3</table></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="4"><nplcit num="4" npl-type="s" extracted-xp="055397258"><text>ANNA CZAJKOWSKA-KO&SACUTE;NIK ET AL: "Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin", MOLECULES, vol. 20, no. 12, 25 November 2015 (2015-11-25), pages 21010 - 21022, XP055397258, DOI: 10.3390/molecules201219745</text><article><author><name>ANNA CZAJKOWSKA-KO&SACUTE;NIK ET AL</name></author><atl>Development and Evaluation of Liquid and Solid Self-Emulsifying Drug Delivery Systems for Atorvastatin</atl><serial><sertitle>MOLECULES</sertitle><pubdate><sdate>20151125</sdate></pubdate><vid>20</vid><ino>12</ino><doi>10.3390/molecules201219745</doi></serial><location><pp><ppf>21010</ppf><ppl>21022</ppl></pp></location></article></nplcit><rel-passage><passage><pp>A</pp><figure>1-2</figure><table>1</table></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="5"><nplcit num="5" npl-type="w" extracted-xp="055966867"><text>DIXIT RAHUL P. ET AL: "Dry Adsorbed Emulsion of Simvastatin: Optimization and In Vivo Advantage", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 12, no. 5, 7 January 2007 (2007-01-07), US, pages 495 - 504, XP055966867, ISSN: 1083-7450, Retrieved from the Internet &lt;URL:http://dx.doi.org/10.1080/10837450701557246&gt; DOI: 10.1080/10837450701557246</text><online><author><name>DIXIT RAHUL P. ET AL</name></author><online-title>Dry Adsorbed Emulsion of Simvastatin: Optimization and In Vivo Advantage</online-title><serial><sertitle>PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY</sertitle><imprint><address><text>US</text></address><name></name></imprint><vid>12</vid><ino>5</ino><doi>10.1080/10837450701557246</doi><issn>1083-7450</issn></serial><pubdate><sdate>20070107</sdate></pubdate><location><pp><ppf>495</ppf><ppl>504</ppl></pp></location><avail>http://dx.doi.org/10.1080/10837450701557246</avail></online></nplcit><rel-passage><passage><pp>A</pp><table>1,2</table></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="6"><nplcit num="6" npl-type="s" extracted-xp="055966943"><text>CHAVHAN SANDIP S. ET AL: "Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies", JOURNAL OF MICROENCAPSULATION., vol. 30, no. 8, 27 December 2013 (2013-12-27), GB, pages 771 - 779, XP055966943, ISSN: 0265-2048, DOI: 10.3109/02652048.2013.788085</text><article><author><name>CHAVHAN SANDIP S. ET AL</name></author><atl>Simvastatin nanoemulsion for improved oral delivery: design, characterisation, in vitro and in vivo studies</atl><serial><sertitle>JOURNAL OF MICROENCAPSULATION.</sertitle><imprint><address><text>GB</text></address><name></name></imprint><pubdate><sdate>20131227</sdate></pubdate><vid>30</vid><ino>8</ino><doi>10.3109/02652048.2013.788085</doi><issn>0265-2048</issn></serial><location><pp><ppf>771</ppf><ppl>779</ppl></pp></location></article></nplcit><rel-passage><passage><pp>A</pp></passage><passage><figure>1</figure></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="7"><patcit num="1" dnum="CN102908333A" dnum-type="publication number"><document-id doc-id="381263225"><country>CN</country><doc-number>102908333</doc-number><kind>A</kind><name>UNIV CHINA PHARMA</name><date>20130206</date></document-id></patcit><rel-passage><passage><pp>A</pp><claim>1-8</claim></passage><passage><para>8-20, 24</para><example>1-3</example></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="8"><patcit num="2" dnum="WO2005013972A1" dnum-type="publication number"><document-id doc-id="282624485"><country>WO</country><doc-number>2005013972</doc-number><kind>A1</kind><name>AVENTIS PHARMA SA [FR]</name><date>20050217</date></document-id></patcit><rel-passage><passage><pp>17</pp><line>10</line><ppl>19</ppl><linel>5</linel></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="9"><nplcit num="7" npl-type="w" extracted-xp="026715210"><text>ELNAGGAR Y S R ET AL: "Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 380, no. 1-2, 1 October 2009 (2009-10-01), pages 133 - 141, XP026715210, ISSN: 0378-5173, [retrieved on 20090725], DOI: 10.1016/J.IJPHARM.2009.07.015</text><online><author><name>ELNAGGAR Y S R ET AL</name></author><online-title>Self-nanoemulsifying drug delivery systems of tamoxifen citrate: Design and optimization</online-title><serial><sertitle>INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL</sertitle><vid>380</vid><ino>1-2</ino><doi>10.1016/J.IJPHARM.2009.07.015</doi><issn>0378-5173</issn></serial><pubdate><sdate>20091001</sdate></pubdate><location><pp><ppf>133</ppf><ppl>141</ppl></pp></location><srchdate><date>20090725</date></srchdate></online></nplcit><rel-passage><passage><table>3-4</table></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="10"><nplcit num="8" npl-type="w" extracted-xp="086186176"><text>HAN HAN ET AL: "A Soluplus/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability", NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 27, 7 April 2020 (2020-04-07), XP086186176, ISSN: 1549-9634, [retrieved on 20200407], DOI: 10.1016/J.NANO.2020.102199</text><online><author><name>HAN HAN ET AL</name></author><online-title>A Soluplus/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability</online-title><serial><sertitle>NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, ELSEVIER, AMSTERDAM, NL</sertitle><vid>27</vid><doi>10.1016/J.NANO.2020.102199</doi><issn>1549-9634</issn></serial><pubdate><sdate>20200407</sdate></pubdate><srchdate><date>20200407</date></srchdate></online></nplcit><rel-passage><passage><pp>A</pp><figure>3</figure></passage><passage><pp>4</pp><column>r</column><para>Pseudo-ternary phase diagram</para></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="11"><patcit num="3" dnum="WO2013147452A1" dnum-type="publication number"><document-id doc-id="410954746"><country>WO</country><doc-number>2013147452</doc-number><kind>A1</kind><name>YUHAN CORP [KR]</name><date>20131003</date></document-id></patcit><rel-passage><passage><example>22, 28</example></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="ISR" cited-date="20220930" srep-office="EP" sequence="12"><patcit num="4" dnum="WO2021005101A1" dnum-type="publication number"><document-id doc-id="544370561"><country>WO</country><doc-number>2021005101</doc-number><kind>A1</kind><name>IDORSIA PHARMACEUTICALS LTD [CH]</name><date>20210114</date></document-id></patcit><rel-passage><passage><example>4, 4a, 5-8</example></passage><category>Y</category><rel-claims>1-32</rel-claims></rel-passage><category>Y</category></exch:citation><exch:citation cited-phase="APP" sequence="1"><nplcit num="1" npl-type="s"><text>CORSINI ABELLOSTA SBAETTA RFUMAGALLI RPAOLETTI RBERNINI F: "New insights into the pharmacodynamic and pharmacokinetic properties of statins", PHARMACOL THER, vol. 84, no. 3, December 1999 (1999-12-01), pages 413 - 28</text><article><author><name>CORSINI ABELLOSTA SBAETTA RFUMAGALLI RPAOLETTI RBERNINI F</name></author><atl>New insights into the pharmacodynamic and pharmacokinetic properties of statins</atl><serial><sertitle>Pharmacol Ther</sertitle><pubdate><sdate>19991200</sdate></pubdate><vid>84</vid><ino>3</ino></serial><location><pp><ppf>413</ppf><ppl>28</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="2"><nplcit num="2" npl-type="s" extracted-xp="022357322"><text>ARMITAGE J: "The safety of statins in clinical practice", THE LANCET, vol. 370, no. 9601, November 2007 (2007-11-01), pages 1781 - 90, XP022357322, DOI: 10.1016/S0140-6736(07)60716-8</text><article><author><name>ARMITAGE J</name></author><atl>The safety of statins in clinical practice</atl><serial><sertitle>The Lancet</sertitle><pubdate><sdate>20071100</sdate></pubdate><vid>370</vid><ino>9601</ino><doi>10.1016/S0140-6736(07)60716-8</doi></serial><location><pp><ppf>1781</ppf><ppl>90</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="3"><nplcit num="3" npl-type="s" extracted-xp="021049646"><text>MRC/BHF HEART PROTECTION STUDY COLLABORATIVE GROUP: "Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people", BMC CLIN PHARMACOL, vol. 9, no. 1, December 2009 (2009-12-01), pages 6, XP021049646</text><article><author><name>MRC/BHF HEART PROTECTION STUDY COLLABORATIVE GROUP</name></author><atl>Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people</atl><serial><sertitle>BMC Clin Pharmacol</sertitle><pubdate><sdate>20091200</sdate></pubdate><vid>9</vid><ino>1</ino></serial><location><pp><ppf>6</ppf></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="4"><nplcit num="4" npl-type="s"><text>GALTIER FMURA TRAYNAUD DE MAUVERGER ECHEVASSUS HFARRET AGAGNOL JP ET AL.: "Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers", TOXICOL APPL PHARMACOL, vol. 263, no. 3, September 2012 (2012-09-01), pages 281 - 6</text><article><author><name>GALTIER FMURA TRAYNAUD DE MAUVERGER ECHEVASSUS HFARRET AGAGNOL JP et al.</name></author><atl>Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers</atl><serial><sertitle>Toxicol Appl Pharmacol</sertitle><pubdate><sdate>20120900</sdate></pubdate><vid>263</vid><ino>3</ino></serial><location><pp><ppf>281</ppf><ppl>6</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="5"><nplcit num="5" npl-type="s" extracted-xp="085413027"><text>CROWE TPGREENLEE MHWKANTHASAMY AGHSU WH: "Mechanism of intranasal drug delivery directly to the brain", LIFE SCI, vol. 195, 15 February 2018 (2018-02-15), pages 44 - 52, XP085413027, DOI: 10.1016/j.lfs.2017.12.025</text><article><author><name>CROWE TPGREENLEE MHWKANTHASAMY AGHSU WH</name></author><atl>Mechanism of intranasal drug delivery directly to the brain</atl><serial><sertitle>Life Sci</sertitle><pubdate><sdate>20180215</sdate></pubdate><vid>195</vid><doi>10.1016/j.lfs.2017.12.025</doi></serial><location><pp><ppf>44</ppf><ppl>52</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="6"><nplcit num="6" npl-type="s"><text>CHAVHAN SSPETKAR KCSAWANT KK: "Simvastatin nanoemulsion for improved oral delivery: Design, characterization, in vitro and in vivo studies", J MICROENCAPSUL, vol. 30, no. 8, 2013, pages 771 - 9</text><article><author><name>CHAVHAN SSPETKAR KCSAWANT KK</name></author><atl>Simvastatin nanoemulsion for improved oral delivery: Design, characterization, in vitro and in vivo studies</atl><serial><sertitle>J Microencapsul</sertitle><pubdate><sdate>20130000</sdate></pubdate><vid>30</vid><ino>8</ino></serial><location><pp><ppf>771</ppf><ppl>9</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="7"><nplcit num="7" npl-type="s" extracted-xp="027210215"><text>NAZIR ASCHROEN KBOOM R: "Premix emulsification: A review", J MEMBER SCI, vol. 362, no. 1-2, 2010, pages 1 - 11, XP027210215</text><article><author><name>NAZIR ASCHROEN KBOOM R</name></author><atl>Premix emulsification: A review</atl><serial><sertitle>J Member Sci</sertitle><pubdate><sdate>20100000</sdate></pubdate><vid>362</vid><ino>1-2</ino></serial><location><pp><ppf>1</ppf><ppl>11</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="8"><nplcit num="8" npl-type="s"><text>PIRES PC, SANTOS LT, RODRIGUES M, ALVES G, SANTOS AO: "November 2021", INT J PHARM, vol. 592, pages 120040</text><article><author><name>PIRES PC, SANTOS LT, RODRIGUES M, ALVES G, SANTOS AO</name></author><atl>November 2021</atl><serial><sertitle>Int J Pharm</sertitle><vid>592</vid></serial><location><pp><ppf>120040</ppf></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="9"><nplcit num="9" npl-type="s"><text>SONVICO F, GARRASTAZU G, BATGER M, RONDELLI V, CANTU L, DEL FAVERO E: "The nasal delivery of nanoencapsulated statins – an approach for brain delivery", INT J NANOMEDICINE, vol. 11, 2016, pages 6575 - 90</text><article><author><name>SONVICO F, GARRASTAZU G, BATGER M, RONDELLI V, CANTU L, DEL FAVERO E</name></author><atl>The nasal delivery of nanoencapsulated statins – an approach for brain delivery</atl><serial><sertitle>Int J Nanomedicine</sertitle><pubdate><sdate>20160000</sdate></pubdate><vid>11</vid></serial><location><pp><ppf>6575</ppf><ppl>90</ppl></pp></location></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="10"><nplcit num="10" npl-type="s"><text>BRUINSMANN FAPIGANA SAGUIRRE TSOUTO GDPEREIRA GGBIANCHERA A ET AL.: "Chitosan-coated nanoparticles: Effect of chitosan molecular weight on nasal transmucosal delivery", PHARMACEUTICS, vol. 11, no. 2, 2019</text><article><author><name>BRUINSMANN FAPIGANA SAGUIRRE TSOUTO GDPEREIRA GGBIANCHERA A et al.</name></author><atl>Chitosan-coated nanoparticles: Effect of chitosan molecular weight on nasal transmucosal delivery</atl><serial><sertitle>Pharmaceutics</sertitle><pubdate><sdate>20190000</sdate></pubdate><vid>11</vid><ino>2</ino></serial></article></nplcit></exch:citation><exch:citation cited-phase="APP" sequence="11"><nplcit num="11" npl-type="s"><text>MANICKAVASAGAM DNOVAK KOYEWUMI MO: "Therapeutic Delivery of Simvastatin Loaded in PLA-PEG Polymers Resulted in Amplification of Antiinflammatory Effects in Activated Microglia", AAPS J, vol. 20, no. 1, 2018, pages 1 - 13</text><article><author><name>MANICKAVASAGAM DNOVAK KOYEWUMI MO</name></author><atl>Therapeutic Delivery of Simvastatin Loaded in PLA-PEG Polymers Resulted in Amplification of Antiinflammatory Effects in Activated Microglia</atl><serial><sertitle>AAPS J</sertitle><pubdate><sdate>20180000</sdate></pubdate><vid>20</vid><ino>1</ino></serial><location><pp><ppf>1</ppf><ppl>13</ppl></pp></location></article></nplcit></exch:citation></exch:references-cited></exch:bibliographic-data><exch:abstract lang="en" data-format="docdba" abstract-source="national office"><exch:p>The present disclosure relates to a self-emulsifying composition and/or a stable and homogeneous aqueous oil-in-water emulsion comprising a neutral hydrophilic surfactant and a combination of at least two hydrophobic excipients selected from the following list: glycerol monooleate, miglyol 812; propylene glycol monocaprylate; wherein 90% of the droplets comprise a size of less than 180 nm; and wherein the size of 50% of the droplets ranges from 90-120 nm. A pharmaceutical composition comprising said emulsion is also described.</exch:p></exch:abstract><exch:abstract lang="fr" data-format="docdba" abstract-source="national office"><exch:p>La présente divulgation concerne une composition auto-émulsifiante et/ou une émulsion aqueuse huile dans l'eau stable et homogène comprenant un tensioactif hydrophile neutre et une combinaison d'au moins deux excipients hydrophobes choisis dans la liste suivante : le monooléate de glycérol ; le miglyol 812 ; et le propylène glycol monocaprylate ; 90 % des gouttelettes comprenant une taille inférieure à 180 nm ; et la taille de 50 % des gouttelettes étant comprise entre 90 et 120 nm. Une composition pharmaceutique comprenant ladite émulsion est également décrite.</exch:p></exch:abstract></exch:exchange-document>
